Despite a daily loss of 5.03% and a 3-month gain of 18.51%, Axonics Inc (NASDAQ:AXNX) recorded a Loss Per Share of 0.67. This raises the question - is the stock significantly undervalued? In this ...

On September 22, 2023, Axonics Inc (NASDAQ:AXNX) reported a 1.95% daily loss, bringing its 3-month gain to 8.53%. Despite a Loss Per Share of $0.67, the question arises: is the stock significantly ...

Axonics Modulation Technologies Inc. is keeping its 220-person team of sales reps and clinical specialists busy. The Irvine-based, urology-focused medical device maker (Nasdaq: AXNX) said late last ...

Medtronic is going after Axonics once again, this time with accusations that its competitor in sacral neuromodulation is illegally using Medtronic’s MRI compatibility technology. The accusations come ...

An Axonics sacral neuromodulation system sends electrical signals to nerves in the spinal cord to help regulate the bladder and bowels Device maker Axonics Inc. says its newest system designed to ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic against Axonics in ...

Memorial Healthcare and Axonics will host a free virtual Community Health Talk titled, “Regaining Bladder Control” at 6 p.m.

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

Axonics focuses on medical products to treat bladder and bowel dysfunction. The company, after the markets closed on Thursday, reported second-quarter revenue of $92.9 million, up 35%, year over year.

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...